Ann: Investor presentation, page-13

You've probably seen this video already, but if you haven't -



Apart from what you already mention, another key catalyst will be the interim trial results for the SNT-5505 Phase 2amyelofibrosiscombination study, which is almost fully recruited for (80% there), locked in to be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. Likely to be a significant inflection point and an opportunity to raise money at a premium, if required.

My primary reasons for investing:
- 1 year cash runway
- 3 or 4 different Phase 2 trial results all due by mid-2025
- Positive data from SNT 5505 monotherapy study! It's interim Ph2 data is due in Dec '24 as mentioned above
- SNT 5505 - demonstrated reduction in bone marrow fibrosis AND demonstrated improvement in scar appearance
- Company has worked with Fiona Wood for 5 years on scar treatment. There are no other pharma treatments in development and Fiona Wood saw the full inhibition of L enzymes, and the 30% reduction of collagen in scars, over only a 3-month period, as UNPRECEDENTED! Trial patients still continue to improve after the end of the trial.
- Management have taken serious steps to reduce costs and stretch funds
- $10m raised late last year from institutions at 2.2c. Platinum Investments increasing their holding from 8-20%. As a friend of mine said - these institutions employ people to do due diligence on their investments - if an investment is good enough for them, then it's good enough for me!
- I haven't checked but CEO advises of a super strong register of investors with 60% being instos
- Focus by company - cancer of the blood and skin scarring
- Huge potential market for just one of these products, let alone more than one. I think market exposure for all was something like $15b!
- Some people, who I value as knowing a lot more about bios than myself, think SNT is an exceptional buying opportunity! Works for me!